Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
578
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,869.00 | 52.50 | -0.59% |
| CAC 40 | 7,873.11 | 45.48 | 0.58% |
| DAX 40 | 25,298.61 | 38.71 | 0.15% |
| Dow JONES (US) | 51,621.48 | 48.62 | -0.09% |
| FTSE 100 | 10,724.86 | 74.53 | 0.70% |
| HKSE | 24,314.17 | 31.05 | -0.13% |
| NASDAQ | 26,692.87 | 511.51 | -1.88% |
| Nikkei 225 | 67,744.29 | 33.23 | -0.05% |
| NZX 50 Index | 13,719.46 | 40.93 | -0.30% |
| S&P 500 | 7,718.94 | 86.51 | -1.11% |
| S&P/ASX 200 | 8,727.90 | 56.00 | -0.64% |
| SSE Composite Index | 3,767.23 | 33.64 | -0.88% |